Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases

Autoimmunity Reviews

Volumn 4, Issue 3, 2005, Pages 162-170

  Botsios, Costantino ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Adalimumab; Anakinra; Etanercept; Infliximab; Safety

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CARDIOLIPIN ANTIBODY; CHIMERIC ANTIBODY; CYCLOSPORIN; CYTOKINE RECEPTOR ANTAGONIST; ETANERCEPT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ALLERGY; ANAPHYLAXIS; APLASTIC ANEMIA; APOPTOSIS; ARTHRALGIA; ASEPTIC MENINGITIS; ASPERGILLOSIS; ATYPICAL MYCOBACTERIOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BACTERIAL ARTHRITIS; BACTERIAL INFECTION; BILE DUCT CARCINOMA; BREAST CARCINOMA; CANCER; CELLULITIS; CHILL; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; COCCIDIOIDOMYCOSIS; COLORECTAL CARCINOMA; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS INFECTION; DEATH; DEMYELINATING DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DIVERTICULITIS; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DYSPHAGIA; DYSPNEA; EDEMA; EMBRYOTOXICITY; ERYSIPELAS; FACE EDEMA; FEVER; GALLBLADDER CARCINOMA; GUILLAIN BARRE SYNDROME; HAND EDEMA; HEADACHE; HEART FAILURE; HEMATOLOGIC DISEASE; HEPATITIS B; HEPATITIS C; HISTOPLASMOSIS; HODGKIN DISEASE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFLAMMATION; INJECTION SITE REACTION; LEUKOPENIA; LIP EDEMA; LISTERIOSIS; LIVER DISEASE; LIVER FAILURE; LUNG TUBERCULOSIS; LUPUS LIKE SYNDROME; LYMPHOMA; MELANOMA; MILIARY TUBERCULOSIS; MONOCYTOPENIA; MULTIPLE SCLEROSIS; MYALGIA; MYELITIS; NAUSEA; NEUROPATHY; NEUTROPENIA; NOCARDIOSIS; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; OPTIC NERVE DISEASE; PANCYTOPENIA; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; POLYRADICULONEUROPATHY; POSTOPERATIVE INFECTION; PREGNANCY; PROSTATE CARCINOMA; PROSTHESIS INFECTION; PRURITUS; PYELONEPHRITIS; RASH; REVIEW; RHEUMATIC DISEASE; RISK; SEIZURE; SIDE EFFECT; SORE THROAT; TERATOGENICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOUS PERITONITIS; URTICARIA; UTERINE CERVIX CARCINOMA; VASCULITIS; VIRUS INFECTION;

EID: 16844386174     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2004.09.001     Document Type: Review

References (40)

1. P.E. Lipsky, D.M. van der Heijde, E.W. St Clair, D.E. Furst, F.C. Breedveld, and J.R. Kalden Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group N. Engl. J. Med. 343 2000 1594 1602
2. L.W. Moreland, S.W. Baumgartner, M.H. Schiff, E.A. Tindall, R.M. Fleischmann, and A.L. Weaver Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein N. Engl. J. Med. 337 1997 141 147
3. M.E. Weinblatt, E.C. Keystone, D.E. Furst, L.W. Moreland, M.H. Weisman, and C.A. Birbara Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial Arthritis Rheum. 48 2003 35 45
4. P.J. Mease, B.S. Goffe, J. Metz, A. VanderStoep, B. Finck, and D.J. Burge Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial Lancet 356 2000 385 390
5. J. Braun, J. Brandt, J. Listing, A. Zink, R. Alten, and G. Burmester Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial Arthritis Rheum. 48 2003 2224 2233
6. D.J. Lovell, E.H. Giannini, A. Reiff, G.D. Cawkwell, E.D. Silverman, and J.J. Nocton Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric rheumatology collaborative study group N. Engl. J. Med. 342 2000 763 769
7. R.M. Fleischmann, J. Schechtman, R. Bennett, M.L. Handel, G.R. Burmester, and J. Tesser Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial Arthritis Rheum. 48 2003 927 934
8. J.L. Flynn, and J. Chan Immunology of tuberculosis Annu. Rev. Immunol. 19 2001 93 129
9. G. Kollias, and D. Kontoyiannis Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments Cytokine Growth Factor Rev. 13 2002 315 321
10. L.J. Old Tumor necrosis factor Science 230 1985 630 632
11. X. Filella, J. Blade, A.L. Guillermo, R. Molina, C. Rozman, and A.M. Ballesta Cytokines (IL-6, TNF-alpha, IL-1 alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma Cancer Detect Prev. 20 1996 52 56
12. S.T. Malik, M.S. Naylor, N. East, A. Oliff, and F.R. Balkwill Cells secreting tumour necrosis factor show enhanced metastasis in nude mice Eur. J. Cancer 26 1990 1031 1034
13. M.H. Freedman, A. Cohen, T. Grunberger, N. Bunin, R.E. Luddy, and E.F. Saunders Central role of tumour necrosis factor, GM-CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogenous leukaemia Br. J. Haematol. 80 1992 40 48
14. V. Barak, B. Nisman, and A. Polliack The tumor necrosis factor family and correlation with disease activity and response to treatment in hairy cell leukemia Eur. J. Haematol. 62 1999 71 75
15. P. Orosz, A. Kruger, M. Hubbe, J. Ruschoff, P. Von Hoegen, and D.N. Mannel Promotion of experimental liver metastasis by tumor necrosis factor Int. J. Cancer 60 1995 867 871
16. N. Olsen, and C. Stein New drugs for rheumatoid arthritis N. Engl. J. Med. 350 2004 2167 2179
17. Food and Drug Administration, Center for Drug Evaluation and Research, Arthritis Advisory Committee. Safety update meeting on TNF blocking agents. March 4, 2003. (http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3930T1.htm).
18. T. Ellerin, R.H. Rubin, and M.E. Weinblatt Infections and anti-tumor necrosis factor-α therapy Arthritis Rheum. 48 2003 3013 3022
19. R.M. Fleischmann, S.W. Baumgartner, E.A. Tindall, A.L. Weaver, L.W. Moreland, and M.H. Schiff Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results J. Rheumatol. 30 2003 691 696
20. M.F. Doran, C.S. Crowson, G.R. Pond, W.M. O'Fallon, and S.E. Gabriel Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study Arthritis Rheum. 46 2002 2287 2293
21. J. Keane, S. Gershon, R.P. Wise, E. Mirabile-Levens, J. Kasznica, and W.D. Schwieterman Tuberculosis associated with infliximab, a tumor necrosis factor-α neutralizing agent N. Engl. J. Med. 345 2001 1098 1104
22. M.A. Gardam, E.C. Keystone, R. Menzies, S. Manners, E. Skamene, and R. Long Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management Lancet, Infect. Dis. 3 2003 148 155
23. B.J. Scallon, H. Trinh, M. Nedelman, F.M. Brennan, M. Feldmann, and J. Ghrayeb Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins Cytokine 7 1995 759 770
24. A. Lugering, M. Schmidt, N. Lugering, H.G. Pauels, W. Domschke, and T. Kucharzik Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase dependent pathway Gastroenterology 121 2001 1145 1157
25. P. Ostuni, C. Botsios, L. Punzi, P. Sfriso, and S. Todesco Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate Ann. Rheum. Dis. 62 2003 686 687
26. C. Botsios, P. Ostuni, P. Sfriso, A. Furlan, U. Fiocco, and D. Sgarabotto Infections in patients with rheumatoid arthritis receiving anti-cytokine therapy: biological mechanisms and clinical aspects Reumatismo 55 2003 224 235
27. E. Baecklund, A. Ekbom, P. Sparen, N. Feltelius, and L. Klareskog Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study BMJ 317 1998 180 181
28. K. Ekstrom, H. Hjalgrim, L. Brandt, E. Baecklund, L. Klareskog, and A. Ekbom Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives Arthritis Rheum. 48 2003 963 970
29. F. Wolfe, and K. Michaud Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients Arthritis Rheum. 50 2004 1740 1751
30. N. Mohan, E.T. Edwards, T.R. Cupps, P.J. Oliverio, G. Sandberg, and H. Crayton Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides Arthritis Rheum. 44 2001 2862 2869
31. B.W. Van Oosten, F. Barkhof, L. Truyen, J.B. Boringa, F.W. Bertelsmann, and B.M. von Blomberg Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2 Neurology 47 1996 1531 1534
32. B. Levine, J. Kalman, L. Mayer, H.M. Fillit, and M. Packer Elevated circulating levels of tumor necrosis factor in severe chronic heart failure N. Engl. J. Med. 323 1990 236 241
33. D. Khanna, M. McMahon, and D.E. Furst Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum 50 2004 1040 1050
34. A. Doria, P.C. Puttini, and Y. Shoenfeld Heart, rheumatism and autoimmunity; Milan, Italy. February 5-7, 2004 Autoimmun. Rev. 3 2004 337 354
35. R.N. Maini, F.C. Breedveld, J.R. Kalden, J.S. Smolen, D. Davis, and J.D. Macfarlane Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis Rheum. 41 1998 1552 1563
36. F. Baert, M. Noman, S. Vermeire, G. Van Assche, G. D'Haens, and A. Carbonez Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease N. Engl. J. Med. 348 2003 601 608
37. T. Jonsdottir, J. Forslid, A. van Vollenhoven, A. Harju, S. Brannemark, and L. Klareskog Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies Ann Rheum. Dis. 63 2004 1075 1078
38. A.K. Mohan, E.T. Edwards, T.R. Cote, J.N. Siegel, and M.M. Braun Drug-induced systemic lupus erythematosus and TNF-alpha blockers Lancet 360 2002 646
39. E.F. Chakravarty, D. Sanchez-Yamamoto, and T.M. Bush The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age J. Rheumatol. 30 2003 241 246
40. J.A. Katz, G.R. Lichtenstein, G.F. Keenan, D.E. Healey, and S.J. Jacobs Outcome of pregnancy in women receiving Remicade (Infliximab) for the treatment of Crohn's disease or rheumatoid arthritis (Abstract) Gastroenterology 120 2001 A69